Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial.

导出 LinkOut

翻译打印收藏纠错

第一作者： Ajay K,Nooka

第一单位： Department of Hematology and Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia.

作者： Ajay K,Nooka ^[1] ; Michael Luhua,Wang ^[2] ; Andrew J,Yee ^[3] ; Jonathan L,Kaufman ^[1] ; Jooeun,Bae ^[4] ; Doris,Peterkin ^[5] ; Paul G,Richardson ^[4] ; Noopur S,Raje ^[3]

作者单位： Department of Hematology and Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia. ^[1] University of Texas MD Anderson Cancer Center, Houston. ^[2] Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, Massachusetts. ^[3] Dana-Farber Cancer Institute, Boston, Massachusetts. ^[4] OncoPep Inc, North Andover, Massachusetts. ^[5]

主题词成年人(Adult);老年人(Aged);老年人, 80以上(Aged, 80 and over);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);癌症疫苗(Cancer Vaccines);队列研究(Cohort Studies);综合疗法(Combined Modality Therapy);剂量效应关系, 药物(Dose-Response Relationship, Drug);女(雌)性(Female);人类(Humans);免疫疗法(Immunotherapy);男(雄)性(Male);中年人(Middle Aged);治疗结果(Treatment Outcome)

DOI 10.1001/jamaoncol.2018.3267

PMID 30128502

发布时间 2020-03-09

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览6

JAMA oncology

2018年4卷12期

e183267页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial.

JAMA oncology

相似文献

JAMA oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial.

JAMA oncology

相似文献

JAMA oncology

相关期刊

检索历史清除